Group 1 - The company, Boji Pharmaceutical, primarily focuses on the research and development of chemical drugs, with significant capabilities in liver disease, digestive disorders, tumors, and endocrine research services [1] - The company also provides services related to traditional Chinese medicine, biological drugs, and medical devices, but chemical drug development is the main area of expertise [1] - There is currently no authoritative statistical data available regarding the market share of the company's services [1]

Core Insights - The CXO (Contract Research Organization and Contract Development and Manufacturing Organization) sector in A-shares shows a mixed performance in the first half of the year, with 19 out of 35 companies reporting a year-on-year profit increase, indicating a positive trend in the industry [1] Group 1: Company Performance - WuXi AppTec leads the CXO companies with a net profit of 5.313 billion yuan, followed by Kelun Pharmaceutical with 1.686 billion yuan, and Tigermed with 1.388 billion yuan [2] - WuXi AppTec's revenue reached 18.871 billion yuan, a year-on-year increase of 6.28%, with a net profit growth of 14.61% [2] - Kelun Pharmaceutical reported a revenue of 4.622 billion yuan, a decline of 8.33%, and a net profit decrease of 3.09% [3] Group 2: Sector Trends - The demand for peptide drugs, traditional Chinese medicine, and ADC (Antibody-Drug Conjugates) is increasing, leading to significant order growth for some CXO companies [4] - WuXi AppTec's TIDES business, focusing on oligonucleotides and peptides, generated 1.33 billion yuan in revenue, a growth of 37.9%, with a backlog of orders increasing by 188% [4] - The CRO service provider Boji Pharmaceutical reported a 49% increase in new business contracts, with traditional Chinese medicine contracts growing by approximately 400% [4] Group 3: Market Expansion - Despite a cooling investment environment in the global pharmaceutical sector, several CXO companies are experiencing growth in overseas markets [5] - Kelun Pharmaceutical's revenue from U.S. clients reached 3.348 billion yuan, with a 44.77% increase when excluding large orders [5] - Tigermed's revenue was 3.711 billion yuan, a year-on-year increase of 3.25%, with a net profit growth of 16.47% [6]